https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Sirtuin Three lack aggravates angiotensin II-induced hypertensive cardiac damage through the disability involving lymphangiogenesis. Subjects will be orally administered 16 mg/kg VGCV twice daily for 6 months. The target number of cases for enrollment between February 3, 2020 and July 31, 2021 is 25. Primary endpoint is the change in whole blood CMV loads before and after 6 months of treatment. The important secondary endpoint is the change in ABR (both be
Like
Comment
Share
